Flexion Therapeutics Inc. (NASDAQ:FLXN) previous close was $8.39 while the outstanding shares total 49.84M. The firm has a beta of 1.38. FLXN’s shares traded higher over the last trading session, gaining 2.98% on 05/20/21. The shares fell to a low of $8.25 before closing at $8.64. Intraday shares traded counted 0.43 million, which was 58.36% higher than its 30-day average trading volume of 1.03M. The stock’s Relative Strength Index (RSI) is 56.07, with weekly volatility at 5.34% and ATR at 0.51. The FLXN stock’s 52-week price range has touched low of $6.71 and a $14.39 high.
Investors have identified the Drug Manufacturers – Specialty & Generic company Flexion Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $418.09 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Flexion Therapeutics Inc. (FLXN) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For FLXN, the company has in raw cash 98.71 million on their books with 18.33 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 204.62 million total, with 57.98 million as their total liabilities.
FLXN were able to record -19.27 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by -9.0 million. In cash movements, the company had a total of -18.47 million as operating cash flow.
Potential earnings growth for Flexion Therapeutics Inc. (FLXN)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/10/2021 quarter of the year, Flexion Therapeutics Inc. recorded a total of 24.59 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 18.15% coming in sequential stages and their sales for the 08/10/2021 quarter reducing by -7.0%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 6.08 million trying to sell their products during the last quarter, with the result yielding a gross income of 18.5 million. This allows shareholders to hold on to 49.84M with the recently reported earning now reading -0.57 cents per share. This is a figure that compared to analyst’s prediction for their 08/10/2021 (-0.57 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.93 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on FLXN sounds very interesting.
Is the stock of FLXN attractive?
In related news, Chief Financial Officer, Arkowitz David sold 2,229 shares of the company’s stock in a transaction that recorded on May 10. The sale was performed at an average price of 7.23, for a total value of 16,116. As the sale deal closes, the Chief Commercial Officer, Layman Melissa now sold 4,520 shares of the company’s stock, valued at 53,336. Also, Chief Commercial Officer, Layman Melissa sold 2,624 shares of the company’s stock in a deal that was recorded on Jan 28. The shares were price at an average price of 12.55 per share, with a total market value of 32,931. Following this completion of acquisition, the Chief Business Officer, Muzikant Adam now holds 4,005 shares of the company’s stock, valued at 44,576. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.70%.